Compass Pathways plc reported a net loss of $93.9 million for the fourth quarter of 2025 and $287.9 million for the full year, a sharp rise from $43.3 million and $155.1 million, respectively, in the same periods of 2024. The larger loss is largely attributable to a $122.6 million non‑cash loss on the fair‑value adjustment of warrant liabilities, compared with $0.0 million in 2024, rather than a deterioration in operating performance.
The company’s cash and cash equivalents stood at $149.6 million as of December 31 2025, not March 24 2026. This balance, combined with a $150 million financing completed in February 2026 and the exercise of $200 million in warrants, gives Compass Pathways a runway that extends into 2028.
CEO Kabir Nath highlighted the progress of COMP360, describing it as “shaping the future of mental healthcare” and noting the company’s readiness to submit an NDA to the FDA in the fourth quarter of 2026. He also announced the launch of a late‑stage PTSD study, underscoring the company’s commitment to expanding its therapeutic portfolio.
Earnings per share for the quarter were $‑1.00, missing analyst consensus of $‑0.40 by $0.60. The miss reflects the impact of the large warrant‑liability adjustment, which is a one‑time accounting charge that does not affect cash flows.
Despite the higher loss, Compass Pathways’ focus remains on advancing COMP360 through Phase 3 trials and preparing for commercial launch by the end of 2026. The extended cash runway and ongoing financing support the company’s strategy to bring a first‑in‑class psychedelic‑based therapy to market, positioning it as a potential leader in the emerging field of psychedelic‑assisted treatment for treatment‑resistant depression.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.